Utility of immunohistochemistry markers in the interpretation of post-high-intensive focussed ultrasound prostate biopsy cores.

World Journal of Urology
Bernhard WalterAndreas Blana

Abstract

To overcome the difficulties in the interpretation of postoperative tumor obtaining biopsy cores for patients who treated their prostate cancer with high-intensity focussed ultrasound (HIFU) therapy. The H&E slides of 58 patients with residual prostate cancer after HIFU treatment were systematically reviewed. Correlation between the pathologist's findings and immunohistochemical expression of MIB-1, alpha-Methyl-Co-Racemase and 34βE-12 staining was analyzed. Mean time from treatment to biopsy was 40.2 (8-208) weeks. The expert review of the H&E slides identified 40 patients with viable carcinoma in the post-HIFU biopsy cores. 18 patients were revised to necrosis-only-tumors. These biopsies were performed not later than 16 weeks after HIFU treatment (median 10.9 weeks, range 8-14). Both MIB-1 and AMACR staining displayed significant differential expression in viable carcinoma (p < 0.001) compared to necrosis tumors. Referring to viable carcinoma tissue, AMACR staining index was significantly rising, the longer treatment dated back from biopsy (p < 0.002). In this context, 34-β-E12 stained negative through all tumor areas and positive in the majority (85%) of the surrounding non-neoplastic epithelium. AMACR and MIB-1 reliably dif...Continue Reading

References

Oct 7, 1997·CA: a Cancer Journal for Clinicians·D G Bostwick
Sep 7, 2000·International Journal of Radiation Oncology, Biology, Physics·J CrookM Abdolell
Feb 19, 2002·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Tomoo ItohKazuo Nagashima
Nov 19, 2003·Journal of Endourology·Stephan Madersbacher, Michael Marberger
Dec 13, 2005·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Mildred B Martens, Jeremy H Keller
May 23, 2007·Archives of Pathology & Laboratory Medicine·David G Bostwick, Isabelle Meiers
Jan 29, 2008·Radiology·Alexander P S KirkhamClare Allen
Feb 19, 2008·Japanese Journal of Clinical Oncology·Satoru MutoShigeo Horie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.